Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.54 |
| ▸ | CTSS | P25774 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171658 | 0.87 | CTSK (0.52) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL30327580 | 0.87 | CTSK (0.52) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL29979228 | 0.85 | CTSK (0.51) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL10076128 | 0.83 | CTSK (0.63) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL17109102 | 0.82 | CTSK (0.51) | CTSKCTSSCTSLCTSBHDAC4 | |
| SCHEMBL1343403 | 0.81 | CTSK (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL1423262 | 0.81 | CTSK (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL24214307 | 0.81 | CTSK (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL6296123 | 0.81 | CTSK (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL205237 | 0.81 | CTSK (0.50) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331750-A1 | Preparation Method for Glufosinate | LIER CHEMICAL CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4230634-A1 | PREPARATION METHOD FOR GLUFOSINATE-AMMONIUM | Lier Chemical Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023001131-A1 | PREPARATION METHOD FOR GLUFOSINATE-AMMONIUM | 利尔化学股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331750-A1 | Preparation Method for Glufosinate | GLUL, ASNS, GDA | CTSK 2841/4885CTSS 1590/4885CTSL 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.